Ginkgo Bioworks Holdings annual ebitda margin
2019
2020
2021
2022
2023
2024
2025
Ginkgo Bioworks Holdings EBITDA Margin Growth & History (DNA)
Ginkgo Bioworks Holdings's ebitda margin was −150.62% for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −150.62% | +68.17 pp |
| 2024 | 2024-12-31 | −218.79% | +96.94 pp |
| 2023 | 2023-12-31 | −315.72% | +137.78 pp |
| 2022 | 2022-12-31 | −453.50% | +119.85 pp |
| 2021 | 2021-12-31 | −573.35% | −412.68 pp |
| 2020 | 2020-12-31 | −160.67% | −48.38 pp |
| 2019 | 2019-12-31 | −112.29% | — |
Ginkgo Bioworks Holdings quarterly ebitda margin
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −229.38% | −119.72 pp |
| Q1 2026 | 2026-03-31 | −300.79% | −127.75 pp |
| Q4 2025 | 2025-12-31 | −134.31% | +66.29 pp |
| Q3 2025 | 2025-09-30 | −192.50% | −149.79 pp |
| Q2 2025 | 2025-06-30 | −109.66% | +256.16 pp |
| Q1 2025 | 2025-03-31 | −173.03% | +262.17 pp |
| Q4 2024 | 2024-12-31 | −200.59% | +274.96 pp |
| Q3 2024 | 2024-09-30 | −42.71% | +435.97 pp |
| Q2 2024 | 2024-06-30 | −365.82% | −159.17 pp |
| Q1 2024 | 2024-03-31 | −435.20% | −191.36 pp |
| Q4 2023 | 2023-12-31 | −475.56% | −256.61 pp |
| Q3 2023 | 2023-09-30 | −478.68% | +494.27 pp |
| Q2 2023 | 2023-06-30 | −206.66% | +235.03 pp |
| Q1 2023 | 2023-03-31 | −243.84% | +151.89 pp |
| Q4 2022 | 2022-12-31 | −218.95% | +910.21 pp |
| Q3 2022 | 2022-09-30 | −972.95% | −949.25 pp |
| Q2 2022 | 2022-06-30 | −441.68% | −320.73 pp |
| Q1 2022 | 2022-03-31 | −395.73% | −278.97 pp |
| Q4 2021 | 2021-12-31 | −1,129.16% | — |
| Q3 2021 | 2021-09-30 | −23.70% | — |
| Q2 2021 | 2021-06-30 | −120.96% | — |
| Q1 2021 | 2021-03-31 | −116.76% | — |
Ginkgo Bioworks Holdings ebitda margin trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's ebitda margin increased from −160.67% to −150.62%, a change of +10.05 percentage points. The latest reported quarter, Q2 2026, shows −229.38%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...